Fondazione Ricerca Traslazionale

This study tests whether giving a combination of immunotherapy (tislelizumab) and chemotherapy before surgery can help more people with stage III PD-L1 positive non-small cell lung cancer have a complete removal of their tumor. About 30 adults who are current or former smokers an…

This study tests whether adding an immune-boosting vaccine (OSE2101) to a standard immunotherapy (cemiplimab) can better clear cancer DNA from the blood of people with advanced non-small cell lung cancer. About 160 participants who have not worsened after initial chemo-immunother…

This study is for people with stage III non-small-cell lung cancer whose cancer has returned after standard chemoradiation and the drug durvalumab. It tests whether adding extra immune therapy or a targeted pill (olaparib) to standard chemotherapy can help them live longer. About…

This study tests a combination of the targeted drug amivantamab plus a single chemotherapy drug in people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon20 insertion). Participants must not have had prior treatment and must be unable to receive st…

This study is for people with non-small cell lung cancer (NSCLC) who are about to start immunotherapy. Researchers want to understand how the body reacts to these treatments by looking for specific antibodies in the blood. The goal is to learn more about why some people respond b…